Expertise in
22
conditions

Dr. Mustapha A. Khalife

Hematology | Oncology
Hendrick Cancer Center
2000 Pine St, 
Abilene, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
22
conditions
Hendrick Cancer Center
2000 Pine St, 
Abilene, TX 

Overview

Mustapha Khalife is a Hematologist and an Oncologist practicing medicine in Abilene, Texas.

Dr. Khalife is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Lung Cancer.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 12 clinical trials. Dr. Khalife is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Cape Cod Hospital
Falmouth Hospital
Holy Cross Hospital
Stephens Memorial Hospital
Hendrick Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Hendrick Cancer Center
2000 Pine St, Abilene, TX 79601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 23, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

2 Total Publications

Molecular pathways and targeted therapy in cholangiocarcinoma.
Molecular pathways and targeted therapy in cholangiocarcinoma.
Journal: Clinical advances in hematology & oncology : H&O
Published: December 19, 2019
Similar Doctors
Expertise in
30
conditions
Dr. Jose J. Vega
Hematology | Oncology
Expertise in
30
conditions
Dr. Jose J. Vega
Hematology | Oncology
Referral may be required

Hendrick Cancer Center

2000 Pine St, 
Abilene, TX 
 (0.1 miles away)
325-670-6340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jose Vega is a Hematologist and an Oncologist practicing medicine in Abilene, Texas. Dr. Vega is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Pleuropulmonary Blastoma, Lung Cancer, and Gastrostomy. Dr. Vega is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Texas Oncology Pharmacy-Abilene

1957 Antilley Rd, 
Abilene, TX 
 (7.0 miles away)
325-692-0188
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Anton Melnyk is an Oncologist practicing medicine in Abilene, Texas. Dr. Melnyk is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Melnyk is currently accepting new patients.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Texas Oncology Pharmacy-Abilene

1957 Antilley Rd, 
Abilene, TX 
 (7.0 miles away)
325-692-0188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ralph Heaven is an Oncologist practicing medicine in Abilene, Texas. Dr. Heaven is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Heaven is currently accepting new patients.

Frequently Asked Questions about Dr. Mustapha A. Khalife

How do I make an appointment with Dr. Mustapha A. Khalife?

You can book an appointment with Dr. Mustapha A. Khalife by calling their office at 325-670-6340. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mustapha A. Khalife a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mustapha A. Khalife is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mustapha A. Khalife specialize in?

While Dr. Mustapha A. Khalife is a Hematology, they have specific expertise in Breast Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mustapha A. Khalife participate in research or clinical trials?

Yes. Dr. Mustapha A. Khalife has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Mustapha A. Khalife's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mustapha A. Khalife accept my insurance?

Dr. Mustapha A. Khalife accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 325-670-6340 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khalife's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile